Skip to content
CMS listens to BIO and understands proposed policies could have harmed patients, innovation
A new suite of rules governing drug rebates in Medicaid has been finalized, removing months of uncertainty about whether the Centers for Medicare and […]
Editors’ Choice
New survey checks pulse on voters’ concerns for innovation and biomanufacturing
Voters want to bolster American manufacturing across biopharmaceutical and biotechnology sectors, according to a new public opinion survey conducted by Morning Consult for the
New survey checks pulse on voters’ concerns for innovation and biomanufacturing Read More »
BIO files amicus brief challenging IRA drug price controls
Drug price controls in the Inflation Reduction Act (IRA) involve unconstitutional coercion and will destroy innovation in transformational treatments that save patients’ lives, the
BIO files amicus brief challenging IRA drug price controls Read More »
House Oversight Committee grills PBM executives over ‘despicable’ practices
The heads of the three largest pharmacy benefit managers (PBMs) were grilled on July 23 by the House Oversight and Accountability Committee, whose new
House Oversight Committee grills PBM executives over ‘despicable’ practices Read More »
BIO Board member and head of BioUtah testify at House field hearing
The House Ways and Means Committee learned how lawmakers can enable progress in biotech from a Biotechnology Innovation Organization (BIO) Board member and the
BIO Board member and head of BioUtah testify at House field hearing Read More »
Unlocking hope: AMP ALS is transforming ALS biomarker research
“ALS is a devastating disease.” This is a common refrain when talking about Amyotrophic Lateral Sclerosis (ALS), a nervous system disease that weakens muscles
Unlocking hope: AMP ALS is transforming ALS biomarker research Read More »
CMS overreach will impede innovation
In implementing the Inflation Reduction Act (IRA), the Centers for Medicare and Medicaid Services (CMS) has made efforts to unnecessarily broaden the law with
CMS overreach will impede innovation Read More »
FDA’s Dr. Califf talks supply chains, clinical trial diversity, and America’s health
Biopharma supply chains, streamlining regulation, and other critical issues came up when the leader of the U.S. agency regulating drugs spoke with the leader
FDA’s Dr. Califf talks supply chains, clinical trial diversity, and America’s health Read More »
Admiral William H. McRaven and BIO CEO John F. Crowley talk hope in biotech
“Biotechnology, that’s a great, big word that just means hope.” That’s what Christopher Reeve said years ago at a BIO International Convention. Little did
Admiral William H. McRaven and BIO CEO John F. Crowley talk hope in biotech Read More »
Dr. Jason Kelly: Teaming up to build our bio future
Lately the world is enraptured with AI and its potential to change our lives. AI transforms our digital world—the world of information. But changing lives
Dr. Jason Kelly: Teaming up to build our bio future Read More »